Outlook Therapeutics (OTLK) Other Working Capital Changes (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Other Working Capital Changes of -$15238.0 for Q1 2026, down 23.17% year-over-year from -$19832.2 in Q1 2025, and down 12.88% quarter-over-quarter from -$13499.0 in Q4 2025.
Outlook Therapeutics (OTLK) Other Working Capital Changes (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Other Working Capital Changes for 8 consecutive years, with -$15238.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 23.17% year-over-year to -$15238.0; the TTM figure through Mar 2026 stood at -$54425.0 (down 189.34% YoY), while the FY2025 annual figure was -$50131.0, down 1568.83% from the prior year.
- Other Working Capital Changes slipped to -$15238.0 in Q1 2026 per OTLK's latest filing, from -$13499.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $3.4 million in Q2 2022 and bottomed at -$5.6 million in Q4 2024.
- Historically, Other Working Capital Changes has averaged -$17907.0 across 5 years, with a median of -$113964.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes soared 77.56% — and 2025, when it sank 330.91%.
- Outlook Therapeutics' Other Working Capital Changes stood at -$11422.0 in 2022, then jumped by 65.6% to -$3929.0 in 2023, then slumped by 207.23% to -$12071.0 in 2024, then decreased by 11.83% to -$13499.0 in 2025, then slipped by 12.88% to -$15238.0 in 2026.
- Business Quant data shows OTLK's Other Working Capital Changes at -$15238.0 in Q1 2026, -$13499.0 in Q4 2025, and -$13007.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.18 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 439,855.00 |
| Dec 31, 2025 | 439,855.00 |
| Dec 31, 2025 | 439,855.00 |
| Sep 30, 2025 | -1.84 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -328,933.00 |
| Jun 30, 2025 | -328,933.00 |
| Jun 30, 2025 | -328,933.00 |
| Mar 31, 2025 | -209,136.00 |
| Mar 31, 2025 | -209,136.00 |
| Mar 31, 2025 | -209,136.00 |
| Dec 31, 2024 | -5.63 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Sep 30, 2024 | -1.10 Mn |
| Sep 30, 2024 | -1.10 Mn |